New teplizumab findings among ADA standards updates

21 June 2021

The American Diabetes Association has issued important updates to the 2021 Standards of Medical Care in Diabetes.

These updates, presented in annotations as the Living Standards of Care, include new data on Provention Bio’s (Nasdaq: PRVB) investigational teplizumab and SGLT2 inhibitors as well as medications’ effects on patients with chronic kidney disease.

"There have been so many exciting advancements in the field of diabetes"The teplizumab update includes evidence from a trial on the anti-CD3 antibody in relatives at risk for type 1 diabetes which demonstrated a delay in the development of type I diabetes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK